SMC rejects Sanofi's Zaltrap, Novartis' Afinitor
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium has denied Sanofi and Novartis' cancer drugs Zaltrap (aflibercept) and Afinitor (everolimus) access to NHS Scotland. The health technology appraisal body deemed that neither drug offered value for money.